Ironwood announced the launch of Duzallo (lesinurad/allopurinol) tablets for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
Duzallo was approved by the Food and Drug Administration (FDA) in August 2017. The fixed-dose product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet. Allopurinol reduces the production of uric acid while lesinurad increases renal excretion of uric acid by selectively inhibiting the action of URAT1, the UA transporter responsible for the majority of renal UA reabsorption.
Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. It carries a Boxed Warning stating that acute renal failure has occurred with lesinurad, one of the components of Duzallo. Treatment should be interrupted if serum creatinine levels rise to >2 times the value when lesinurad treatment was initiated.
Duzallo is available as 200mg/200mg and 200mg/300mg strengths in 5-, 30-, and 90-count bottles.
For more information call (844) 374-4793 or visit DuzalloHCP.com.